Avidity Biosciences, Inc. announced the appointment of experienced global commercial and operations executive, Eric Mosbrooker to its board of directors. Mr. Mosbrooker is an industry leader with expertise in building global commercial organizations, as well as marketing, market access, distribution, and compliance. The company also announced the departure of Roderick Wong, M.D. from the board. Dr. Wong, managing partner and chief investment officer at RTW Investments, LP, joined Avidity's board in November 2019 in conjunction with the company's series C financing. Mr. Mosbrooker has expertise in gene therapy, rare metabolic diseases, additional orphan conditions and oncology. Mr. Mosbrooker currently serves as the chief operations officer for Cognoa, leading the commercial, program management, product, and business operations functions. Prior to joining Cognoa, he was the chief commercial officer at Audentes Therapeutics overseeing the gene therapy business unit. Mr. Mosbrooker also served as the senior vice president of the Global Orphan Business Unit at Horizon Pharmaceuticals. He holds a B.S. in Industrial Engineering from the University of Wisconsin – Madison.